蒙脱石散辅助治疗肠易激综合症的临床观察  

作　　者：邱卫东 

机构地区：[1]广东省东莞市企石医院,523500

出　　处：《当代医学》2010年第9期37-37,23,共2页Contemporary Medicine

摘　　要：目的探讨蒙脱石散治疗肠易激综合症(IBS)的临床疗效和安全性。方法将我科从2005年6月至2009年6月间收治的96例肠易激综合症患者随机分为两组,治疗组48例,口服丽珠肠乐2片/次,bid,口服,加用蒙脱石散3g/次,tid,冲服。对照组48例,口服丽珠肠乐2片/次,bid,口服。两组均治疗4周。观察两组治疗后症状改善情况及有效率。结果治疗组总有效率为91.7%,对照组总有效率为72.9%,两组比较差异显著(P<0.01)。两组均未出现严重不良反应。结论蒙脱石散辅助治疗肠易激综合症疗效显著,副作用小,值得推广应用。Objective To observe the clinical efficacy and safety of montmorillonite powder treatment of IBS. Methods My Section from June 2005 to June 2009 were treated 96 cases between irritable bowel syndrome were randomly divided into two groups, treatment group, 48 cases of oral Lizhuchangle 2/time, bid, oral. Canada with montmorillonite powder 3g/times, tid, Granules. The control group, 48 cases of oral Lizhuchangle 2/ time, bid, orally. Both groups were treated for 4 weeks. Symptoms were observed after treatment to improve the situation and efficient. Results The treatment group, the total effective rate was 91.7% in the control group, the total effective rate was 72.9%, a significant difference between the two groups（P〈0.01）. Both groups no serious adverse reactions. Conclusion Montmorillonite powder adjuvant treatment of irritable bowel syndrome, efficacy of significant side effects, is worth popularizing.

关 键 词：蒙脱石散 肠易激综合征 丽珠肠乐 

分 类 号：R574[医药卫生—消化系统]